TY - JOUR
T1 - In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor
AU - Mohanam, Sanjeeva
AU - Chintala, Shravan K.
AU - Go, Yoshinori
AU - Bhattacharya, Anuradha
AU - Venkaiah, Boyapati
AU - Boyd, Douglas
AU - Gokaslan, Ziya L.
AU - Sawaya, Raymond
AU - Rao, Jasti S.
N1 - Funding Information:
Correspondence: JS Rao *The first two authors equally contributed to the work described in this paper Supported in part, by NCI grant CA56792, and ACS grant EDT-91 (JS Rao) and CA 58311 (D Boyd) Received 6 June 1996; revised 15 November 1996; accepted 15 November 1996
PY - 1997
Y1 - 1997
N2 - The cell surface urokinase-type plasminogen activator receptor (uPAR) has been shown to be a key molecule in regulating plasminogen-mediated extracellular proteolysis. To investigate the role of uPAR in invasion of brain tumors, human glioblastoma cell line SNB19 was stably transfected with a vector capable of expressing an antisense transcript complementary to the 300 base pair of the 5' end of the uPAR mRNA. Parental and stably transfected (vector, sense, and antisense) cell lines were analysed for uPAR mRNA transcript by Northern blot analysis, and receptor protein levels were measured by radioreceptor assays and Western blotting. Significant reduction of uPAR sites was observed in the antisense transfected cell lines. The levels of uPAR mRNA were significantly decreased in antisense clones compared to control, vector and sense clones. The invasive potential of the cell lines in vitro was measured by Matrigel invasion assay and migration of cells from spheroids to monolayers. The antisense transfected cells showed a markedly lower level of invasion and migration than the controls. The antisense clones were more adhesive to the ECM components compared to parental, vector and sense clones. All transfected (vector, sense and antisense) clones and parental cells produced similar levels of uPA activity without any significant difference however, MMP-2 activity was decreased in antisense clones compared to controls. These results demonstrate that uPAR expression is critical for the invasiveness of human gliomas and down regulation of uPAR expression may be a feasible approach to decrease invasiveness.
AB - The cell surface urokinase-type plasminogen activator receptor (uPAR) has been shown to be a key molecule in regulating plasminogen-mediated extracellular proteolysis. To investigate the role of uPAR in invasion of brain tumors, human glioblastoma cell line SNB19 was stably transfected with a vector capable of expressing an antisense transcript complementary to the 300 base pair of the 5' end of the uPAR mRNA. Parental and stably transfected (vector, sense, and antisense) cell lines were analysed for uPAR mRNA transcript by Northern blot analysis, and receptor protein levels were measured by radioreceptor assays and Western blotting. Significant reduction of uPAR sites was observed in the antisense transfected cell lines. The levels of uPAR mRNA were significantly decreased in antisense clones compared to control, vector and sense clones. The invasive potential of the cell lines in vitro was measured by Matrigel invasion assay and migration of cells from spheroids to monolayers. The antisense transfected cells showed a markedly lower level of invasion and migration than the controls. The antisense clones were more adhesive to the ECM components compared to parental, vector and sense clones. All transfected (vector, sense and antisense) clones and parental cells produced similar levels of uPA activity without any significant difference however, MMP-2 activity was decreased in antisense clones compared to controls. These results demonstrate that uPAR expression is critical for the invasiveness of human gliomas and down regulation of uPAR expression may be a feasible approach to decrease invasiveness.
KW - Glioblastoma
KW - Invasiveness
KW - Plasminogen activators
KW - Receptors
UR - http://www.scopus.com/inward/record.url?scp=0030899731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030899731&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1200963
DO - 10.1038/sj.onc.1200963
M3 - Article
C2 - 9178895
AN - SCOPUS:0030899731
VL - 14
SP - 1351
EP - 1359
JO - Oncogene
JF - Oncogene
SN - 0950-9232
IS - 11
ER -